Delgocitinib preparation involves a specific process, and the patent US10822354 describes an improved method for its preparation [1]. This patent claims a pharmaceutical composition containing delgocitinib and its salts, as well as a method for preparing delgocitinib, which aims to reduce impurities and enhance yield [1].
What impurities does the delgocitinib preparation patent address?
The patent US10822354 focuses on controlling specific impurities during the preparation of delgocitinib. It details methods to minimize the presence of related substances, such as degradation products and process-related impurities, thereby improving the purity of the final active pharmaceutical ingredient [1].
When does the delgocitinib preparation patent expire?
Patent expiration dates are crucial for understanding market exclusivity. For US10822354, the patent term is subject to standard patent law provisions, including potential extensions. DrugPatentWatch.com tracks patent statuses and expiration dates for pharmaceuticals, offering detailed information on when such exclusivity might end [2].
What is delgocitinib used for?
Delgocitinib is a Janus kinase (JAK) inhibitor. It is used in the treatment of atopic dermatitis, a type of eczema, by targeting inflammatory pathways in the skin [3].
How does delgocitinib work?
Delgocitinib inhibits JAK enzymes, specifically JAK1, JAK2, JAK3, and TYK2. By blocking these enzymes, it interferes with signaling pathways that contribute to inflammation and immune responses, which are key factors in conditions like atopic dermatitis [3].
Who manufactures delgocitinib?
Torii Pharmaceutical Co., Ltd. developed delgocitinib. It is marketed under the brand name Spexio in Japan for the treatment of atopic dermatitis [3].